A Real World Study Comparing Safety Of Certolizumab Pegol (CZP) With Other Tumour Necrosis Factor Inhibitor (TNFi) Agents In Patients With Rheumatoid Arthritis:A National US Cohort Study.

Trial Profile

A Real World Study Comparing Safety Of Certolizumab Pegol (CZP) With Other Tumour Necrosis Factor Inhibitor (TNFi) Agents In Patients With Rheumatoid Arthritis:A National US Cohort Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jan 2017

At a glance

  • Drugs Certolizumab pegol (Primary) ; Adalimumab; Etanercept; Golimumab; Infliximab
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top